Dear Editor,Chronic urticaria (CU) is a group of common and debilitating conditions containing both chronic spontaneous urticaria (CSU) and chronic inducible urticarias (CIndU) including cold urticaria (ColdU). While antihistamines and omalizumab are effective treatments for both CSU and ColdU, many patients show insufficient response to either or both of these treatments, and additional and better therapies are needed.Reslizumab is a humanized monoclonal anti‐interleukin 5 (IL‐5) antibody licensed for the treatment of severe eosinophilic asthma. IL‐5 is the major cytokine responsible for the recruitment, activation and survival of eosinophils, which play a crucial role in causing tissue and subsequent airway hyperresponsiveness in asthma. Previously, we demonstrated that eosinophil numbers are increased in the skin of CSU patients. Recently, we reported that treatment with mepolizumab, another monoclonal antibody against IL‐5, can result in the rapid remission of CSU.Here, we report the case of a 43‐year‐old woman with severe non‐allergic refractory eosinophilic asthma (non‐smoker, IgE 136 kU/L, skin prick test negative to pollen, mites and other common aeroallergens, eosinophils 540/μL, FEV1 75% predicted, asthma control test (ACT) 15 points, four asthma exacerbations in the last year, therapy including prednisolone 50–25 mg/day, LAMA and LABA) who was successfully treated for her asthma with
Journal of the European Academy of Dermatology & Venereology – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera